ASAHI INTECC CO.,LTD. [7747.T]
TOKYO, Apr 09 (Pulse News Wire) – ASAHI INTECC CO.,LTD. (7747.T) announced today that its board of directors approved an exclusive sales agreement for the medical device Nexsphere-F™, developed and manufactured by Korean firm NEXTBIOMEDICAL CO., LTD.
Once regulatory approval is obtained, ASAHI INTECC plans to launch direct hospital sales through its subsidiary ASAHI INTECC J SALES CO.,LTD. The contract duration is five years post-insurance coverage, with annual renewals thereafter. Nexsphere-F is a temporary embolic agent used in Transcatheter Arterial Micro-EMBOLIZATION (TAME) treatments abroad.
ASAHI INTECC expects to leverage its existing network and expertise to promote the product's adoption alongside related offerings such as abdominal micro-catheters and guidewires. The company anticipates contributing to improved quality of life for chronic pain patients through this innovative treatment option. Additionally, Nexsphere-F is currently sold in Europe via direct sales channels in France, Germany, and Italy, supporting ongoing efforts to expand TAME therapy.
ASAHI INTECC believes the product holds significant potential in the Japanese market based on clinical evidence gathered so far.
🟢 Confidence: High AI-translated content.